FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220761775> ?p ?o ?g. }

• W4220761775 abstract "Breast cancer is the most frequent type of malignancy in women worldwide, and drug resistance to the available systemic therapies remains a major challenge. At the molecular level, breast cancer is heterogeneous, where the cancer-initiating stem-like cells (bCSCs) comprise a small yet distinct population of cells within the tumor microenvironment (TME) that can differentiate into cells of multiple lineages, displaying varying degrees of cellular differentiation, enhanced metastatic potential, invasiveness, and resistance to radio- and chemotherapy. Based on the expression of estrogen and progesterone hormone receptors, expression of human epidermal growth factor receptor 2 (HER2), and/or BRCA mutations, the breast cancer molecular subtypes are identified as TNBC, HER2 enriched, luminal A, and luminal B. Management of breast cancer primarily involves resection of the tumor, followed by radiotherapy, and systemic therapies including endocrine therapies for hormone-responsive breast cancers; HER2-targeted therapy for HER2-enriched breast cancers; chemotherapy and poly (ADP-ribose) polymerase inhibitors for TNBC, and the recent development of immunotherapy. However, the complex crosstalk between the malignant cells and stromal cells in the breast TME, rewiring of the many different signaling networks, and bCSC-mediated processes, all contribute to overall drug resistance in breast cancer. However, strategically targeting bCSCs to reverse chemoresistance and increase drug sensitivity is an underexplored stream in breast cancer research. The recent identification of dysregulated miRNAs/ncRNAs/mRNAs signatures in bCSCs and their crosstalk with many cellular signaling pathways has uncovered promising molecular leads to be used as potential therapeutic targets in drug-resistant situations. Moreover, therapies that can induce alternate forms of regulated cell death including ferroptosis, pyroptosis, and immunotherapy; drugs targeting bCSC metabolism; and nanoparticle therapy are the upcoming approaches to target the bCSCs overcome drug resistance. Thus, individualizing treatment strategies will eliminate the minimal residual disease, resulting in better pathological and complete response in drug-resistant scenarios. This review summarizes basic understanding of breast cancer subtypes, concept of bCSCs, molecular basis of drug resistance, dysregulated miRNAs/ncRNAs patterns in bCSCs, and future perspective of developing anticancer therapeutics to address breast cancer drug resistance." @default.
• W4220761775 created "2022-04-03" @default.
• W4220761775 creator A5066811021 @default.
• W4220761775 creator A5082217666 @default.
• W4220761775 date "2022-03-21" @default.
• W4220761775 modified "2023-09-30" @default.
• W4220761775 title "Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance" @default.
• W4220761775 cites W1256125786 @default.
• W4220761775 cites W141123821 @default.
• W4220761775 cites W1438161774 @default.
• W4220761775 cites W1502235898 @default.
• W4220761775 cites W1571546772 @default.
• W4220761775 cites W1735670763 @default.
• W4220761775 cites W1750541550 @default.
• W4220761775 cites W1773149959 @default.
• W4220761775 cites W1781390342 @default.
• W4220761775 cites W1809740262 @default.
• W4220761775 cites W1828378256 @default.
• W4220761775 cites W1874478038 @default.
• W4220761775 cites W1919584830 @default.
• W4220761775 cites W1949743561 @default.
• W4220761775 cites W1967304777 @default.
• W4220761775 cites W1967618767 @default.
• W4220761775 cites W1972642182 @default.
• W4220761775 cites W1975812656 @default.
• W4220761775 cites W1976324983 @default.
• W4220761775 cites W1977807649 @default.
• W4220761775 cites W1977846137 @default.
• W4220761775 cites W1983201135 @default.
• W4220761775 cites W1983889487 @default.
• W4220761775 cites W1983985456 @default.
• W4220761775 cites W1985339653 @default.
• W4220761775 cites W1986406178 @default.
• W4220761775 cites W1988072378 @default.
• W4220761775 cites W1988485005 @default.
• W4220761775 cites W1990879144 @default.
• W4220761775 cites W1991726426 @default.
• W4220761775 cites W1992473950 @default.
• W4220761775 cites W1992533338 @default.
• W4220761775 cites W1993842564 @default.
• W4220761775 cites W1994130324 @default.
• W4220761775 cites W1995189063 @default.
• W4220761775 cites W1996376317 @default.
• W4220761775 cites W1997280228 @default.
• W4220761775 cites W1997847812 @default.
• W4220761775 cites W1999251458 @default.
• W4220761775 cites W2002490399 @default.
• W4220761775 cites W2004941068 @default.
• W4220761775 cites W2005895632 @default.
• W4220761775 cites W2006986876 @default.
• W4220761775 cites W2008955962 @default.
• W4220761775 cites W2011705265 @default.
• W4220761775 cites W2013956549 @default.
• W4220761775 cites W2014691022 @default.
• W4220761775 cites W2015831734 @default.
• W4220761775 cites W2019311111 @default.
• W4220761775 cites W2023316892 @default.
• W4220761775 cites W2023427658 @default.
• W4220761775 cites W2023560061 @default.
• W4220761775 cites W2023906705 @default.
• W4220761775 cites W2024002740 @default.
• W4220761775 cites W2026691651 @default.
• W4220761775 cites W2028593825 @default.
• W4220761775 cites W2030510623 @default.
• W4220761775 cites W2031126441 @default.
• W4220761775 cites W2032012444 @default.
• W4220761775 cites W2033671499 @default.
• W4220761775 cites W2034145807 @default.
• W4220761775 cites W2035880310 @default.
• W4220761775 cites W2036796232 @default.
• W4220761775 cites W2037342985 @default.
• W4220761775 cites W2037353097 @default.
• W4220761775 cites W2038121235 @default.
• W4220761775 cites W2039720316 @default.
• W4220761775 cites W2042110498 @default.
• W4220761775 cites W2042198997 @default.
• W4220761775 cites W2044166564 @default.
• W4220761775 cites W2044702943 @default.
• W4220761775 cites W2047172303 @default.
• W4220761775 cites W2049460219 @default.
• W4220761775 cites W2050300062 @default.
• W4220761775 cites W2054541267 @default.
• W4220761775 cites W2056772956 @default.
• W4220761775 cites W2058443035 @default.
• W4220761775 cites W2058763255 @default.
• W4220761775 cites W2059411043 @default.
• W4220761775 cites W2061879199 @default.
• W4220761775 cites W2065196942 @default.
• W4220761775 cites W2069104846 @default.
• W4220761775 cites W2069588389 @default.
• W4220761775 cites W2073931568 @default.
• W4220761775 cites W2079032404 @default.
• W4220761775 cites W2080232352 @default.
• W4220761775 cites W2082229511 @default.
• W4220761775 cites W2082839004 @default.
• W4220761775 cites W2083293423 @default.
• W4220761775 cites W2085101164 @default.
• W4220761775 cites W2088231318 @default.
• W4220761775 cites W2093500494 @default.
• W4220761775 cites W2094091051 @default.

• next